UK P3BEP - A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours (UK P3BEP)
Recipient organisationNIHR Wellcome Trust Birmingham Clinical Research Facility
NIHR supportRecorded as supported by this research centre
PeriodFeb 2025 — Dec 2026
In plain English
AI plain-English summary
Chemotherapy cycles for men with advanced testicular cancer could be cut from three weeks to two, in a trial testing whether a faster regimen saves more lives. Germ cell tumours, which cause 98% of testicular cancers, respond well to treatment in most cases. But over a third of patients with metastatic disease eventually relapse and die despite current best therapy. The standard BEP chemotherapy regimen—bleomycin, etoposide, and cisplatin—is given in 21-day cycles. Early safety trials suggest that compressing these cycles to 14 days is feasible and no more toxic. This phase 3 trial will randomise patients with intermediate or poor-risk germ cell tumours to receive either four 21-day cycles or four 14-day cycles of BEP, followed by weekly bleomycin. The primary endpoint is progression-free survival. Secondary outcomes include overall survival, adverse events, quality of life, and treatment preference. If accelerated BEP proves superior, it could become the new standard first-line therapy for these high-risk patients, potentially improving survival rates without increasing toxicity. The shorter schedule also means less time on treatment for patients—a practical benefit that matters to people facing months of chemotherapy.
View original technical description
Germ cell tumours (GCTs) account for 98% of all testicular cancers. Germ cell tumours also arise in the ovary, accounting for 1% to 2% of ovarian neoplasms. Germ cell tumours also rarely arise in the mediastinum, retroperitoneum, ovary and brain. Post-pubertal germ cell tumours represent 14% of all cancers in older adolescents. Outcomes are excellent for most patients, however over a third of patients with metastatic disease will relapse and die despite being on the best available therapy. There is a need to improve 1st line therapy results for patients classified as intermediate & poor risk. Treatment currently involves the use of a chemotherapy regimen comprising of bleomycin, etoposide, & cisplatin (BEP)? coupled with surgical resection of residual metastatic disease post chemotherapy. Early trials have demonstrated the safety, feasibility & tolerability of accelerated BEP for metastatic GCTs. These trials also indicated that the chemotherapy related toxicities were no worse than those expected from standard BEP regimen. This is an open-label, randomised, stratified 2-arm multicentre phase 3 clinical trial in patients with intermediate or poor risk categorised GCTs undertaken in two stages. The patients will be given either 4 x 21-day cycles of BEP or 4 x 14-day cycles of BEP, followed by 4 doses of weekly bleomycin monotherapy. The aim of the study is to determine if accelerated BEP is superior to standard BEP as a 1st line therapy for these patient groups by comparing progression-free survival in the two arms. The research team will also compare the two arms for protocol specific response, adverse events, quality of life and treatment preference, delivered dose-intensity of chemotherapy & overall survival.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know